NYSE:HIMS Hims & Hers Health (HIMS) Stock Forecast, Price & News $6.15 +0.14 (+2.33%) (As of 02:57 PM ET) Add Compare Share Share Today's Range$5.93▼$6.2150-Day Range$6.02▼$9.1352-Week Range$4.01▼$12.34Volume1.00 million shsAverage Volume3.06 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$11.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Hims & Hers Health MarketRank™ ForecastAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside89.8% Upside$11.75 Price TargetShort InterestHealthy12.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.14Based on 11 Articles This WeekInsider TradingSelling Shares$2.25 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.15) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector354th out of 963 stocksOffices & Clinics Of Medical Doctors Industry1st out of 7 stocks 3.4 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.75, Hims & Hers Health has a forecasted upside of 89.8% from its current price of $6.19.Amount of Analyst CoverageHims & Hers Health has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.36% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Hims & Hers Health has recently decreased by 5.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 1.6 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Hims & Hers Health this week, compared to 4 articles on an average week.Search InterestOnly 14 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows19 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 90% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,245,169.00 in company stock.Percentage Held by Insiders31.63% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.45% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow in the coming year, from ($0.15) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hims & Hers Health (NYSE:HIMS) StockHims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.Read More HIMS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesSeptember 19, 2023 | marketbeat.com2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally Beauty stocks have not been pretty this year. Cosmetics retailer Ulta Beauty Inc. (NASDAQ: ULTA) and Estee Lauder Co. (NYSE: EL) sharesSeptember 25, 2023 | seekingalpha.comHims & Hers Health: Can't Get Much BetterSeptember 25, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 25, 2023 | americanbankingnews.comHims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $42,666.32 in StockSeptember 22, 2023 | msn.comHims and Hers Stock Analysis: Buy or Sell?September 21, 2023 | msn.comHims & Hers: Myopic Shorts, Absurdly CheapSeptember 21, 2023 | msn.comHims & Hers Health: Risks Remain, But Upgrading To BuySeptember 18, 2023 | msn.comThe Market Is Wrong On Hims & Hers HealthSeptember 25, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 6, 2023 | finance.yahoo.comHims & Hers Named on Fortune Media and Great Place to Work’s 2023 Best Workplaces in Health Care ListSeptember 6, 2023 | msn.comIs This Underrated SPAC Deal Stock a No-Brainer Buy?August 24, 2023 | finance.yahoo.comWith 60% institutional ownership, Hims & Hers Health, Inc. (NYSE:HIMS) is a favorite amongst the big gunsAugust 21, 2023 | msn.comHims & Hers: Buying With Both Fists (Double Rating Upgrade)August 16, 2023 | seekingalpha.comHims & Hers Q2 Earnings: Portfolio CureAugust 16, 2023 | msn.comHims & Hers: Divergence Between Fundamentals And ValuationAugust 15, 2023 | msn.comHims & Hers: Niche Telehealth Player With Huge PotentialAugust 15, 2023 | seekingalpha.comHims & Hers: The Current Weakness Creates A Buying OpportunityAugust 9, 2023 | forbes.comHims (ED) Review 2023August 9, 2023 | msn.comTruist Securities Maintains Hims & Hers Health Inc - (HIMS) Hold RecommendationAugust 9, 2023 | finance.yahoo.comHims & Hers Health, Inc. (NYSE:HIMS) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | msn.comIs Hims & Hers Health Stock a Must Buy Under $10?August 9, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Hold Rating for Hims & Hers Health (HIMS)August 9, 2023 | markets.businessinsider.comHims & Hers Health Reports Q2 Earnings, Beating Top And Bottom Lines, Raises GuidanceAugust 8, 2023 | msn.comHims & Hers Will Offer Weight-Loss Drugs, But Not the Ones You Are Thinking OfAugust 8, 2023 | msn.comHims & Hers Health Stock (NYSE:HIMS): An Opportunity to Get Your Blood PumpingAugust 8, 2023 | msn.comCredit Suisse Reiterates Hims & Hers Health Inc - (HIMS) Outperform RecommendationAugust 8, 2023 | finance.yahoo.comQ2 2023 Hims & Hers Health Inc Earnings CallSee More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HIMS Company Calendar Last Earnings8/07/2023Today9/25/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Offices & clinics of medical doctors Sub-IndustryN/A SectorMedical Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees651Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.75 High Stock Price Forecast$18.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+95.5%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,680,000.00 Net Margins-6.61% Pretax Margin-6.58% Return on Equity-14.97% Return on Assets-12.40% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.20 Sales & Book Value Annual Sales$526.92 million Price / Sales2.41 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book4.01Miscellaneous Outstanding Shares211,020,000Free Float144,276,000Market Cap$1.27 billion OptionableOptionable Beta0.53 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 34)Co-Founder, Chairman & CEO Comp: $1.7MMr. Yemi Okupe (Age 37)Chief Financial Officer Comp: $804.05kMs. Melissa Baird (Age 45)Chief Operating Officer Comp: $917.67kMs. Irene A. Becklund (Age 38)Sr. VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Soleil Teubner Boughton (Age 44)Chief Legal Officer & Corp. Sec. Comp: $782.66kMr. Mike Chi (Age 43)Chief Marketing Officer Comp: $514.77kDr. Patrick Carroll M.D. (Age 65)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $27.03kMr. Brian O'ShaughnessyChief Communications OfficerMs. Amee ParekhSr. VP of HRMr. Jonathan Spitzer C.F.A.Sr. VP of Investor RelationsMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCVir BiotechnologyNASDAQ:VIRAmneal PharmaceuticalsNYSE:AMRXSummit TherapeuticsNASDAQ:SMMTEstablishment LabsNASDAQ:ESTAView All CompetitorsInsiders & InstitutionsOluyemi OkupeSold 6,794 sharesTotal: $42,666.32 ($6.28/share)Irene BecklundSold 10,596 sharesTotal: $66,860.76 ($6.31/share)Lynne Chou O'keefeSold 10,045 sharesTotal: $63,383.95 ($6.31/share)Melissa BairdSold 9,133 sharesTotal: $62,104.40 ($6.80/share)Melissa BairdSold 9,133 sharesTotal: $62,743.71 ($6.87/share)View All Insider TransactionsView All Institutional Transactions HIMS Stock - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price forecast for 2023? 10 Wall Street analysts have issued 12 month price objectives for Hims & Hers Health's stock. Their HIMS share price forecasts range from $5.00 to $18.00. On average, they anticipate the company's share price to reach $11.75 in the next year. This suggests a possible upside of 95.5% from the stock's current price. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2023? Hims & Hers Health's stock was trading at $6.41 on January 1st, 2023. Since then, HIMS stock has decreased by 6.2% and is now trading at $6.01. View the best growth stocks for 2023 here. Are investors shorting Hims & Hers Health? Hims & Hers Health saw a drop in short interest in August. As of August 31st, there was short interest totaling 16,650,000 shares, a drop of 5.8% from the August 15th total of 17,680,000 shares. Based on an average daily volume of 2,990,000 shares, the days-to-cover ratio is presently 5.6 days. Currently, 12.4% of the company's shares are short sold. View Hims & Hers Health's Short Interest. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our HIMS earnings forecast. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) released its earnings results on Monday, August, 7th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03. The firm earned $207.91 million during the quarter, compared to the consensus estimate of $204.95 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 14.97% and a negative net margin of 6.61%. The company's revenue for the quarter was up 83.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.10) EPS. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Amplify Online Retail ETF (IBUY), Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Hims & Hers Health issued on next quarter's earnings? Hims & Hers Health updated its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $217.00 million-$222.00 million, compared to the consensus revenue estimate of $213.78 million. What is Hims & Hers Health's stock symbol? Hims & Hers Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HIMS." Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.74%), Marshall Wace LLP (2.78%), State Street Corp (1.42%), Nuveen Asset Management LLC (1.37%), Nuveen Asset Management LLC (1.37%) and Geode Capital Management LLC (1.13%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Hims & Hers Health's stock price today? One share of HIMS stock can currently be purchased for approximately $6.01. How much money does Hims & Hers Health make? Hims & Hers Health (NYSE:HIMS) has a market capitalization of $1.27 billion and generates $526.92 million in revenue each year. The company earns $-65,680,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. How many employees does Hims & Hers Health have? The company employs 651 workers across the globe. How can I contact Hims & Hers Health? Hims & Hers Health's mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The official website for the company is www.forhims.com. The company can be reached via phone at 415-851-0195 or via email at hims-ir@westwicke.com. This page (NYSE:HIMS) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.